Pharmacokinetic analysis of new synthetic antimalarial N-251

Kazuaki Okada, Akira Sato, Akiko Hiramoto, Rena Isogawa, Yuji Kurosaki, Kazutaka Higaki, Shin-ichi Miyoshi, Kyung Soo Chang, Hye-Sook Kim

Research output: Contribution to journalArticle

Abstract

Background: With the emergence and growing number of drug-resistant Plasmodium falciparum, a new drug for malaria control must be urgently developed. The new antimalarial synthetic compound N-251 was recently discovered. As an endoperoxide structure in the body, the compound shows high antimalarial activity and curative effects. We performed a pharmacokinetic (PK) analysis of N-251 under various conditions using mice to understand the inhibitory effect of N-251 in parasite-infected mice. Results: PK study of N-251 after intravenous and oral administration in mice showed plasma concentration of N-251 was decreased drastically by intravenous route. C max was reached in 2 h after oral administration of N-251, and the level decreased to a level similar to that obtained after intravenous administration. The area under the curves (AUCs) of the plasma concentration of N-251 increased dose-proportionally in both administrations, and bioavailability (F) was approximately 23%. Additionally, T max, C max, AUC, and F increased in fasted mice compared to normal-fed mice after the administration of N-251, indicating the influence of diet on the absorption kinetics of N-251. Furthermore, in parasite-infected fasted mice, the plasma concentration-time profile of N-251 was similar to that in normal-fasted mice. Based on the PK parameters of single oral administration of N-251, we investigated the effect of multiple oral doses of N-251 (68 mg/kg three times per day for 2 days) in normal-fed mice. The plasma concentration of N-251 was between 10 and 1000 ng/mL. The simulation curve calculated based on the PK parameters obtained from the single-dose study well described the plasma concentrations after multiple oral dosing, indicating that N-251 did not accumulate in the mice. Multiple oral administrations of N-251 in mice were required to completely eliminate parasites without accumulation of N-251. Conclusions: N-251 has been selected as a potent antimalarial candidate. We found that N-251 showed short half-life in plasma, and AUCs increased proportionally to dose. With multiple doses of N-251, the plasma level of N-251 was greater than 10 ng/mL in normal-fed mice, and accumulation of N-251 was not observed; however, multiple treatments with N-251 are required for the complete cure of parasite-infected mice. Determining the appropriate dosage was an important step in the clinical applications of N-251.

Original languageEnglish
Article number40
JournalTropical Medicine and Health
Volume47
Issue number1
DOIs
Publication statusPublished - Jul 5 2019

Fingerprint

Antimalarials
Pharmacokinetics
Oral Administration
Parasites
Area Under Curve
Intravenous Administration
Drug and Narcotic Control
Plasmodium falciparum
Biological Availability
Malaria
Half-Life
Diet

Keywords

  • 6-(1 2 6 7-tetraoxaspiro [7.11] nonadec-4-yl)hexan-1-ol (N-251)
  • Antimalarial medicine
  • Bioavailability (F)
  • Pharmacokinetic (PK) study
  • Synthetic endoperoxide

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Pharmacokinetic analysis of new synthetic antimalarial N-251. / Okada, Kazuaki; Sato, Akira; Hiramoto, Akiko; Isogawa, Rena; Kurosaki, Yuji; Higaki, Kazutaka; Miyoshi, Shin-ichi; Chang, Kyung Soo; Kim, Hye-Sook.

In: Tropical Medicine and Health, Vol. 47, No. 1, 40, 05.07.2019.

Research output: Contribution to journalArticle

Okada, Kazuaki ; Sato, Akira ; Hiramoto, Akiko ; Isogawa, Rena ; Kurosaki, Yuji ; Higaki, Kazutaka ; Miyoshi, Shin-ichi ; Chang, Kyung Soo ; Kim, Hye-Sook. / Pharmacokinetic analysis of new synthetic antimalarial N-251. In: Tropical Medicine and Health. 2019 ; Vol. 47, No. 1.
@article{c27313a171944e44b054b583a2555ca9,
title = "Pharmacokinetic analysis of new synthetic antimalarial N-251",
abstract = "Background: With the emergence and growing number of drug-resistant Plasmodium falciparum, a new drug for malaria control must be urgently developed. The new antimalarial synthetic compound N-251 was recently discovered. As an endoperoxide structure in the body, the compound shows high antimalarial activity and curative effects. We performed a pharmacokinetic (PK) analysis of N-251 under various conditions using mice to understand the inhibitory effect of N-251 in parasite-infected mice. Results: PK study of N-251 after intravenous and oral administration in mice showed plasma concentration of N-251 was decreased drastically by intravenous route. C max was reached in 2 h after oral administration of N-251, and the level decreased to a level similar to that obtained after intravenous administration. The area under the curves (AUCs) of the plasma concentration of N-251 increased dose-proportionally in both administrations, and bioavailability (F) was approximately 23{\%}. Additionally, T max, C max, AUC, and F increased in fasted mice compared to normal-fed mice after the administration of N-251, indicating the influence of diet on the absorption kinetics of N-251. Furthermore, in parasite-infected fasted mice, the plasma concentration-time profile of N-251 was similar to that in normal-fasted mice. Based on the PK parameters of single oral administration of N-251, we investigated the effect of multiple oral doses of N-251 (68 mg/kg three times per day for 2 days) in normal-fed mice. The plasma concentration of N-251 was between 10 and 1000 ng/mL. The simulation curve calculated based on the PK parameters obtained from the single-dose study well described the plasma concentrations after multiple oral dosing, indicating that N-251 did not accumulate in the mice. Multiple oral administrations of N-251 in mice were required to completely eliminate parasites without accumulation of N-251. Conclusions: N-251 has been selected as a potent antimalarial candidate. We found that N-251 showed short half-life in plasma, and AUCs increased proportionally to dose. With multiple doses of N-251, the plasma level of N-251 was greater than 10 ng/mL in normal-fed mice, and accumulation of N-251 was not observed; however, multiple treatments with N-251 are required for the complete cure of parasite-infected mice. Determining the appropriate dosage was an important step in the clinical applications of N-251.",
keywords = "6-(1 2 6 7-tetraoxaspiro [7.11] nonadec-4-yl)hexan-1-ol (N-251), Antimalarial medicine, Bioavailability (F), Pharmacokinetic (PK) study, Synthetic endoperoxide",
author = "Kazuaki Okada and Akira Sato and Akiko Hiramoto and Rena Isogawa and Yuji Kurosaki and Kazutaka Higaki and Shin-ichi Miyoshi and Chang, {Kyung Soo} and Hye-Sook Kim",
year = "2019",
month = "7",
day = "5",
doi = "10.1186/s41182-019-0167-4",
language = "English",
volume = "47",
journal = "Tropical Medicine and Health",
issn = "1348-8945",
publisher = "Japanese Society of Tropical Medicine",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic analysis of new synthetic antimalarial N-251

AU - Okada, Kazuaki

AU - Sato, Akira

AU - Hiramoto, Akiko

AU - Isogawa, Rena

AU - Kurosaki, Yuji

AU - Higaki, Kazutaka

AU - Miyoshi, Shin-ichi

AU - Chang, Kyung Soo

AU - Kim, Hye-Sook

PY - 2019/7/5

Y1 - 2019/7/5

N2 - Background: With the emergence and growing number of drug-resistant Plasmodium falciparum, a new drug for malaria control must be urgently developed. The new antimalarial synthetic compound N-251 was recently discovered. As an endoperoxide structure in the body, the compound shows high antimalarial activity and curative effects. We performed a pharmacokinetic (PK) analysis of N-251 under various conditions using mice to understand the inhibitory effect of N-251 in parasite-infected mice. Results: PK study of N-251 after intravenous and oral administration in mice showed plasma concentration of N-251 was decreased drastically by intravenous route. C max was reached in 2 h after oral administration of N-251, and the level decreased to a level similar to that obtained after intravenous administration. The area under the curves (AUCs) of the plasma concentration of N-251 increased dose-proportionally in both administrations, and bioavailability (F) was approximately 23%. Additionally, T max, C max, AUC, and F increased in fasted mice compared to normal-fed mice after the administration of N-251, indicating the influence of diet on the absorption kinetics of N-251. Furthermore, in parasite-infected fasted mice, the plasma concentration-time profile of N-251 was similar to that in normal-fasted mice. Based on the PK parameters of single oral administration of N-251, we investigated the effect of multiple oral doses of N-251 (68 mg/kg three times per day for 2 days) in normal-fed mice. The plasma concentration of N-251 was between 10 and 1000 ng/mL. The simulation curve calculated based on the PK parameters obtained from the single-dose study well described the plasma concentrations after multiple oral dosing, indicating that N-251 did not accumulate in the mice. Multiple oral administrations of N-251 in mice were required to completely eliminate parasites without accumulation of N-251. Conclusions: N-251 has been selected as a potent antimalarial candidate. We found that N-251 showed short half-life in plasma, and AUCs increased proportionally to dose. With multiple doses of N-251, the plasma level of N-251 was greater than 10 ng/mL in normal-fed mice, and accumulation of N-251 was not observed; however, multiple treatments with N-251 are required for the complete cure of parasite-infected mice. Determining the appropriate dosage was an important step in the clinical applications of N-251.

AB - Background: With the emergence and growing number of drug-resistant Plasmodium falciparum, a new drug for malaria control must be urgently developed. The new antimalarial synthetic compound N-251 was recently discovered. As an endoperoxide structure in the body, the compound shows high antimalarial activity and curative effects. We performed a pharmacokinetic (PK) analysis of N-251 under various conditions using mice to understand the inhibitory effect of N-251 in parasite-infected mice. Results: PK study of N-251 after intravenous and oral administration in mice showed plasma concentration of N-251 was decreased drastically by intravenous route. C max was reached in 2 h after oral administration of N-251, and the level decreased to a level similar to that obtained after intravenous administration. The area under the curves (AUCs) of the plasma concentration of N-251 increased dose-proportionally in both administrations, and bioavailability (F) was approximately 23%. Additionally, T max, C max, AUC, and F increased in fasted mice compared to normal-fed mice after the administration of N-251, indicating the influence of diet on the absorption kinetics of N-251. Furthermore, in parasite-infected fasted mice, the plasma concentration-time profile of N-251 was similar to that in normal-fasted mice. Based on the PK parameters of single oral administration of N-251, we investigated the effect of multiple oral doses of N-251 (68 mg/kg three times per day for 2 days) in normal-fed mice. The plasma concentration of N-251 was between 10 and 1000 ng/mL. The simulation curve calculated based on the PK parameters obtained from the single-dose study well described the plasma concentrations after multiple oral dosing, indicating that N-251 did not accumulate in the mice. Multiple oral administrations of N-251 in mice were required to completely eliminate parasites without accumulation of N-251. Conclusions: N-251 has been selected as a potent antimalarial candidate. We found that N-251 showed short half-life in plasma, and AUCs increased proportionally to dose. With multiple doses of N-251, the plasma level of N-251 was greater than 10 ng/mL in normal-fed mice, and accumulation of N-251 was not observed; however, multiple treatments with N-251 are required for the complete cure of parasite-infected mice. Determining the appropriate dosage was an important step in the clinical applications of N-251.

KW - 6-(1 2 6 7-tetraoxaspiro [7.11] nonadec-4-yl)hexan-1-ol (N-251)

KW - Antimalarial medicine

KW - Bioavailability (F)

KW - Pharmacokinetic (PK) study

KW - Synthetic endoperoxide

UR - http://www.scopus.com/inward/record.url?scp=85068701189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068701189&partnerID=8YFLogxK

U2 - 10.1186/s41182-019-0167-4

DO - 10.1186/s41182-019-0167-4

M3 - Article

AN - SCOPUS:85068701189

VL - 47

JO - Tropical Medicine and Health

JF - Tropical Medicine and Health

SN - 1348-8945

IS - 1

M1 - 40

ER -